Table 3.
Recommendations |
---|
●There is no evidence that either insulin aspart or insulin lispro has adverse effects on pregnancy or on the foetus |
●Insulin lispro and insulin aspart have advantages over RHI during pregnancy |
●lower risk of hypoglycaemia |
●lower post‐prandial glucose excursions |
●improved overall glycaemic control |
●better patient satisfaction |
●Insulin lispro and insulin aspart may offer benefits over NPH |
●greater flexibility |
●improved glycaemic control |
●The use of insulin glulisine is not recommended because of a lack of relevant safety data |
NPH, neutral protamine Hagedorn; RHI, regular human insulin